Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295406 | 1.00 | TSHR (0.65) | TSHRGABRA1GABRB2LMNAPOLB | |
| SCHEMBL12610425 | 1.00 | TSHR (0.65) | TSHRGABRA1GABRB2LMNAPOLB | |
| SCHEMBL9757096 | 0.90 | TSHR (0.55) | TSHRGABRA1GABRB2LMNAPOLB | |
| Cadaverine Tartrate SCHEMBL1649361 | 0.87 | TSHR (0.52) | TSHRGABRA1GABRB2LMNAPOLB | |
| SCHEMBL30172716 | 0.85 | LMNA (0.61) | TSHRGABRA1GABRB2LMNAADRB1 | |
| SCHEMBL5107136 | 0.85 | LMNA (0.61) | TSHRGABRA1GABRB2LMNAADRB1 | |
| SCHEMBL5107130 | 0.85 | LMNA (0.61) | TSHRGABRA1GABRB2LMNAADRB1 | |
| SCHEMBL5107133 | 0.85 | LMNA (0.61) | TSHRGABRA1GABRB2LMNAADRB1 | |
| SCHEMBL4738271 | 0.83 | TSHR (0.55) | TSHRGABRA1GABRB2LMNAPOLB | |
| SCHEMBL2989016 | 0.83 | TSHR (0.55) | TSHRGABRA1GABRB2LMNAADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836262-A | Separation of dialkylene phenol glycol ethers | 陶氏环球技术有限责任公司 | 2024-04-05 | — | — | CN | claimed |
| CN-112336660-A | Eye cream for relieving asthenopia and preparation method thereof | 四川福怡长者文化传播有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-109988213-A | A kind of compound and its preparation method and application for peptide synthesis in liquid phase carrier | 深圳翰宇药业股份有限公司 | 2019-07-09 | — | — | CN | claimed |
| CN-109988062-A | A kind of liquid phase ball type carrier and its preparation method and application | 深圳翰宇药业股份有限公司 | 2019-07-09 | — | — | CN | claimed |
| EP-0446865-B1 | Gelation of acrylamide-containing polymers with hydroxyphenyl alkanols | PHILLIPS PETROLEUM CO (US) | 1994-09-21 | — | — | EP | claimed |
| US-5100931-A | Crosslinking; enhanced oil recovery | PHILLIPS PETROLEUM COMPANY (US) | 1992-03-31 | — | — | US | claimed |
| EP-0446865-A2 | Gelation of acrylamide-containing polymers with hydroxyphenyl alkanols | PHILLIPS PETROLEUM COMPANY (US) | 1991-09-18 | — | — | EP | claimed |
| JP-6321747-A | — | — | None | — | — | JP | disclosed |
| US-20250161259-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4502609-A2 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12201604-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240350451-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240293355-A1 | METHOD OF TREATMENT | VANDA PHARMACEUTICALS INC. | 2024-09-05 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920131-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989012628-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0348155-A1 | Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-12-27 | — | — | EP | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| US-4029713-A | ANTIOXIDANTS | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-3957883-A | PROCESS FOR OXIDIZING ORGANIC COMPOUNDS TO PEROXIDES | ATLANTIC RESEARCH CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201604-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | TSHR 646/4885GABRA1 877/4885GABRB2 698/4885 |
| US-20250161259-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | TSHR 646/4885GABRA1 877/4885GABRB2 698/4885 |
| US-20240293355-A1 | METHOD OF TREATMENT | METTL3, MTNR1B, HCRTR2 | TSHR 1579/4885GABRA1 2312/4885GABRB2 1866/4885 |
| US-20240350451-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | TSHR 642/4885GABRA1 882/4885GABRB2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.